Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

NCT01746251 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

92

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Afatinib

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]